3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Melanoma
3
Lung Neoplasms
3
Colitis
3
Urogenital Neoplasms
2
Solid Carcinoma
2
Diarrhea
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Kidney Neoplasms
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
Gastrointestinal Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Advanced Gastric Cancer
1
Interventions
Cyclophosphamide
29
fludarabine
19
Rituximab
15
fludarabine phosphate
12
Specimen Handling
8
obinutuzumab
7
Immunotherapy, Adoptive
7
Lenalidomide
6
Etoposide
6
pirtobrutinib
5
ibrutinib
5
glofitamab
5
axicabtagene ciloleucel
5
Whole-Body Irradiation
5
Mycophenolic Acid
5
venetoclax
4
polatuzumab vedotin
4
Prednisone
4
Melphalan
4
Granulocyte Colony-Stimulating Factor
4
Doxorubicin
4
Blood Component Removal
4
Biopsy
4
pembrolizumab
3
daratumumab
3
X-Rays
3
Vincristine
3
Stem Cell Transplantation
3
Interleukin-2
3
Injections
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphoma, Non-Hodgkin
×
Fecal Microbiota Transplantation
×
Clear all
NCT04935684
2023-03-01
TMF-Allo
University Hospital, Clermont-Ferrand
Phase 2
Recruiting
150 enrolled